Purinergic signaling in infectious diseases of the central nervous system

dc.creatorSantos Alves, Vinícius
dc.creatorLeite-Aguiar, Raíssa
dc.creatorPereira da Silva, Joyce
dc.creatorCoutinho-Silva, Robson
dc.creatorBaggio Savio, Luiz Eduardo
dc.date.accessioned2020-08-07T15:27:30Z
dc.date.available2020-08-07T15:27:30Z
dc.date.created2020
dc.description.abstractThe incidence of infectious diseases affecting the central nervous system (CNS) has been increasing over the last several years. Among the reasons for the expansion of these diseases and the appearance of new neuropathogens are globalization, global warming, and the increased proximity between humans and wild animals due to human activities such as deforestation. Neurotropism affecting normal brain function is shared by organisms such as viruses, bacteria, fungi, and parasites. Neuroinfections caused by these agents activate immune responses, inducing neuroinflammation, excitotoxicity, and neurodegeneration. Purinergic signaling is an evolutionarily conserved signaling pathway associated with these neuropathologies. During neuroinfections, host cells release ATP as an extracellular danger signal with pro-inflammatory activities. ATP is metabolized to its derivatives by ectonucleotidases such as CD39 and CD73; ATP and its metabolites modulate neuronal and immune mechanisms through P1 and P2 purinergic receptors that are involved in pathophysiological mechanisms of neuroinfections. In this review we discuss the beneficial or deleterious effects of various components of the purinergic signaling pathway in infectious diseases that affect the CNS, including human immunodeficiency virus (HIV-1) infection, herpes simplex virus type 1 (HSV-1) infection, bacterial meningitis, sepsis, cryptococcosis, toxoplasmosis, and malaria. We also provide a description of this signaling pathway in emerging viral infections with neurological implications such as Zika and SARS-CoV-2.spa
dc.format.extent40 páginasspa
dc.format.mimetypeimage/jepgspa
dc.identifier.doihttps://doi.org/10.1016/j.bbi.2020.07.026spa
dc.identifier.issn0889-1591spa
dc.identifier.otherhttps://doi.org/10.1016/j.bbi.2020.07.026spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/11748
dc.publisherBrain, Behavior, and Immunityspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.rights.localAcceso restringidospa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectNeuroinfectionsspa
dc.subjectNeuroinflammationspa
dc.subjectCerebral toxoplasmosisspa
dc.subjectZikaspa
dc.subjectSARSCoV-2spa
dc.subjectP2 receptorspa
dc.subjectCD39spa
dc.subjectCD73spa
dc.subjectAdenosinespa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titlePurinergic signaling in infectious diseases of the central nervous systemspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 2 de 2
Cargando...
Miniatura
Nombre:
Captura.PNG
Tamaño:
114.8 KB
Formato:
Portable Network Graphics
Descripción:
Ver portada
Cargando...
Miniatura
Nombre:
Purinergic-signaling-in-infectious-diseases-of-the-_2020_Brain--Behavior--an.pdf
Tamaño:
849.37 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo reservado

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: